{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T02:36:05Z","timestamp":1785551765551,"version":"3.56.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.eprac.2024.12.019","type":"journal-article","created":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T00:43:26Z","timestamp":1735346606000},"page":"419-425","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and Safety of Low-Dose Tolvaptan (7.5\u00a0mg) in the Treatment of Inpatient Hyponatremia: A Retrospective Study"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9453-0975","authenticated-orcid":false,"given":"David C.","family":"Llewellyn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"O\u0161tarija\u0161","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheyaam","family":"Sahadevan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thitikorn","family":"Nuamek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrine","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Royce P.","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios K.","family":"Dimitriadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon JB.","family":"Aylwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eprac.2024.12.019_bib1","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7861\/clinmedicine.17-3-263","article-title":"Hyponatremia - presentations and management","volume":"17","author":"Dineen","year":"2017","journal-title":"Clin Med"},{"key":"10.1016\/j.eprac.2024.12.019_bib2","doi-asserted-by":"crossref","DOI":"10.1177\/1758835919877725","article-title":"Syndrome of inappropriate anti-diuretic hormone secretion in cancer patients: results of the first multicenter Italian study","volume":"11","author":"Berardi","year":"2019","journal-title":"Therapeutic advances in medical oncology"},{"key":"10.1016\/j.eprac.2024.12.019_bib3","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-13-1020","article-title":"Clinical practice guideline on diagnosis and treatment of hyponatremia","volume":"170","author":"Spasovski","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.eprac.2024.12.019_bib4","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1007\/s40618-022-01807-5","article-title":"The V2 receptor antagonist tolvaptan counteracts proliferation and invasivity in human cancer cells","volume":"45","author":"Marroncini","year":"2022","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.eprac.2024.12.019_bib5","doi-asserted-by":"crossref","first-page":"5721","DOI":"10.1007\/s12325-021-01947-9","article-title":"Using tolvaptan to treat hyponatremia: results from a post-authorization pharmacovigilance study","volume":"38","author":"Estilo","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.eprac.2024.12.019_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222312950","article-title":"Updates and perspectives on aquaporin-2 and water balance disorders","volume":"22","author":"Noda","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.eprac.2024.12.019_bib7","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1159\/000086019","article-title":"Consequences of inadequate management of hyponatremia","volume":"25","author":"Adrogu\u00e9","year":"2005","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.eprac.2024.12.019_bib8","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1185\/03007995.2015.1072706","article-title":"\u2018Dos and don\u2019ts\u2019 in the management of hyponatremia","volume":"31","author":"Aylwin","year":"2015","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.eprac.2024.12.019_bib9","doi-asserted-by":"crossref","DOI":"10.1177\/20420188221097343","article-title":"The management of acute and chronic hyponatremia","volume":"13","author":"Lawless","year":"2022","journal-title":"Therapeutic advances in endocrinology and metabolism"},{"key":"10.1016\/j.eprac.2024.12.019_bib10","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/cen.13315","article-title":"A\u00a0systematic review of known interventions for the treatment of chronic nonhypovolaemic hypotonic hyponatremia and a meta-analysis of the vaptans","volume":"86","author":"Bhandari","year":"2017","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.eprac.2024.12.019_bib13","doi-asserted-by":"crossref","DOI":"10.1093\/ehjcr\/ytab183","article-title":"Resistant hyponatremia in a patient with follicular lymphoma and heart failure with reduced ejection fraction: a case report","volume":"5","author":"Butler","year":"2021","journal-title":"European heart journal. Case reports"},{"key":"10.1016\/j.eprac.2024.12.019_bib14","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1253\/circrep.CR-19-0064","article-title":"Long-term tolvaptan treatment in refractory heart failure","volume":"1","author":"Imamura","year":"2019","journal-title":"Circulation reports"},{"key":"10.1016\/j.eprac.2024.12.019_bib15","doi-asserted-by":"crossref","first-page":"5582","DOI":"10.3390\/ijms22115582","article-title":"Management of cirrhotic ascites under the add-on administration of tolvaptan","volume":"22","author":"Adachi","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.eprac.2024.12.019_bib16","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/hepr.13337","article-title":"Effect of tolvaptan on the prognosis of patients with hepatic ascites","volume":"49","author":"Hiramine","year":"2019","journal-title":"Hepatol Res"},{"key":"10.1016\/j.eprac.2024.12.019_bib17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12902-017-0214-2","article-title":"In-patient Tolvaptan use in SIADH: care audit,\u00a0therapy observation and outcome analysis","volume":"17","author":"Humayun","year":"2017","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.eprac.2024.12.019_bib18","article-title":"Interventions for chronic non-hypovolaemic hypotonic hyponatremia","volume":"6","author":"Nagler","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eprac.2024.12.019_bib19","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1530\/EJE-10-1078","article-title":"Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion","volume":"164","author":"Verbalis","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.eprac.2024.12.019_bib20","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s12325-020-01560-2","article-title":"Real-world, non-interventional, retrospective study (SAMPLE) of tolvaptan in patients with hyponatraemia secondary to the syndrome of inappropriate antidiuretic hormone secretion","volume":"38","author":"Pose-Reino","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.eprac.2024.12.019_bib21","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s11739-016-1508-5","article-title":"Efficacy and safety of two different tolvaptan doses in the treatment of hyponatremia in the Emergency Department","volume":"12","author":"Castello","year":"2017","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.eprac.2024.12.019_bib22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1507\/endocrj.EJ20-0216","article-title":"Open-label, multicenter, dose-titration study to determine the efficacy and safety of tolvaptan in Japanese patients with hyponatremia secondary to syndrome of inappropriate secretion of antidiuretic hormone","volume":"68","author":"Arima","year":"2021","journal-title":"Endocr J"},{"key":"10.1016\/j.eprac.2024.12.019_bib23","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.xkme.2019.09.004","article-title":"Equivalent efficacy and decreased rate of overcorrection in patients with syndrome of inappropriate secretion of antidiuretic hormone given very low-dose tolvaptan","volume":"2","author":"Hanna","year":"2020","journal-title":"Kidney Medicine"},{"key":"10.1016\/j.eprac.2024.12.019_bib25","doi-asserted-by":"crossref","first-page":"e4766","DOI":"10.1210\/clinem\/dgab131","article-title":"Clinical experience of the efficacy and safety of low-dose tolvaptan therapy in a UK tertiary Oncology setting","volume":"106","author":"Chatzimavridou-Grigoriadou","year":"2021","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2024.12.019_bib26","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/cen.12943","article-title":"Real-life experience of tolvaptan use in the treatment of severe hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion","volume":"84","author":"Tzoulis","year":"2016","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.eprac.2024.12.019_bib27","article-title":"Tolvaptan versus fluid restriction in the treatment of hyponatremia resulting from SIADH following pituitary surgery","volume":"4","author":"Kleindienst","year":"2020","journal-title":"J\u00a0Endoc Soc"},{"key":"10.1016\/j.eprac.2024.12.019_bib29","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1007\/s00228-017-2302-7","article-title":"Low-dose tolvaptan PK\/PD: comparison of patients with hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion to healthy adults","volume":"73","author":"Shoaf","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.eprac.2024.12.019_bib30","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3904\/kjim.2016.155","article-title":"Comparison of tolvaptan treatment between patients with the SIADH and congestive heart failure: a single-center experience","volume":"33","author":"Park","year":"2018","journal-title":"Kor J Intern Med"},{"issue":"Suppl 1","key":"10.1016\/j.eprac.2024.12.019_bib31","first-page":"7","article-title":"Consensus document on the management of hyponatremia of the acqua group of the Spanish society of Endocrinology and nutrition","volume":"70","author":"Barajas","year":"2023","journal-title":"Endocrinol Diabetes Nutr (Engl Ed)"},{"issue":"12","key":"10.1016\/j.eprac.2024.12.019_bib32","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1373\/clinchem.2015.242602","article-title":"Reference change values for sodium are ignored by the American and European treatment guidelines for hyponatremia","volume":"61","author":"Tormey","year":"2015","journal-title":"Clin Chem"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X24008796?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X24008796?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T11:42:05Z","timestamp":1744717325000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X24008796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1530891X24008796"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2024.12.019","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Low-Dose Tolvaptan (7.5\u00a0mg) in the Treatment of Inpatient Hyponatremia: A Retrospective Study","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2024.12.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 AACE. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}